Skylark Therapeutics establishes operations at Stevenage Bioscience Catalyst

  • Published on 4th February 2022 by Skylark Therapeutics
Share

SkylarkTx has established lab and office facilities at the Stevenage Bioscience Catalyst, the UK’s leading cell and gene therapy hub.

David Venables, SkylarkTx CEO, commented ‘SBC provides an ideal home for Skylark to initiate operations, establish lab facilities and to build its Team. The world class environment allows us to work alongside leading companies in the CGTC space and will help foster a dynamic and collaborative working environment.’

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.